MS Clinical Trials in Massachusetts

55 active trials · 31 recruiting

55 active multiple sclerosis clinical trials have at least one study site in Massachusetts, 31 of them currently recruiting participants. Trials are listed from ClinicalTrials.gov and cover disease-modifying therapies, symptom treatments, rehabilitation and imaging studies.

Eligibility, contact details and the exact site address are on each trial's ClinicalTrials.gov record, linked from every trial page. MS Buddy also lists 15 MS treatment centers in Massachusetts; many trial sites are run from those centers, and your neurologist is the best first person to ask about joining a study.

Active MS trials with sites in Massachusetts

RecruitingPhase 3

Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab

Sponsor: TG Therapeutics, Inc.

Ublituximab · Placebo

25 states800 participantsDetails ›

RecruitingPhase 3

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

Sponsor: Novartis Pharmaceuticals

Remibrutinib oral treatment · Ocrelizumab

18 states360 participantsDetails ›

RecruitingPhase 2

A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)

Sponsor: Hoffmann-La Roche

Ocrelizumab Test Formulation · Ocrelizumab Reference Formulation

8 states182 participantsDetails ›

RecruitingPhase 1

A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis

Sponsor: Hoffmann-La Roche

RO7121932 IV · RO7121932 SC

5 states129 participantsDetails ›

RecruitingPhase 1

Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer

Sponsor: National Cancer Institute (NCI)

Biospecimen Collection · Nivolumab

19 states300 participantsDetails ›

RecruitingPhase 2

A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity

Sponsor: Celgene

BMS-986368 · Placebo

11 states200 participantsDetails ›

RecruitingPhase 4

Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Ocrelizumab · Placebo for Ocrelizumab

9 states123 participantsDetails ›

RecruitingPhase 3

Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis

Sponsor: Sanofi

Frexalimab · Teriflunomide

35 states1600 participantsDetails ›

RecruitingPhase 4

Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis

Sponsor: MGH Institute of Health Professions

Dalfampridine 10 MG [Ampyra] · Physical therapy

1 state48 participantsDetails ›

Recruiting

A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

Sponsor: TG Therapeutics, Inc.

No Intervention

29 states500 participantsDetails ›

RecruitingPhase 3

Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis

Sponsor: Sanofi

Frexalimab · Placebo

38 states900 participantsDetails ›

RecruitingPhase 1

A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

CC-97540 · Fludarabine

14 states120 participantsDetails ›

RecruitingPhase 1

Molecular Imaging of NET Using [C-11]MRB-PET in MS

Sponsor: Brigham and Women's Hospital

[C-11]Methylreboxetine

1 state19 participantsDetails ›

RecruitingPhase 1

PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases

Sponsor: Brigham and Women's Hospital

[F-18]PBR06 · [C-11]PBR28

1 state250 participantsDetails ›

RecruitingNA

Confirmatory Trial for Alleviating Fatigue in Multiple Sclerosis

Sponsor: Accelerated Cure Project for Multiple Sclerosis

Online Program for Fatigue

6 states2000 participantsDetails ›

RecruitingPhase 1

Assessment of Synaptic Density in MS

Sponsor: Brigham and Women's Hospital

[F-18]SDM-8

1 state30 participantsDetails ›

RecruitingPhase 4

Glucose Consumption in MS Using [F-18]FDG-PET

Sponsor: Brigham and Women's Hospital

[F-18]FDG

1 state50 participantsDetails ›

RecruitingPhase 3

Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Autologous Hematopoietic Stem Cell Tr… · Best Available Therapy (BAT)

15 states156 participantsDetails ›

RecruitingPhase 2

A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years

Sponsor: ModernaTX, Inc.

mRNA-1195 · Placebo

5 states180 participantsDetails ›

Recruiting

A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease

Sponsor: TScan Therapeutics, Inc.

Companion blood samples with procedure

9 states300 participantsDetails ›

Recruiting

Care in Multiple Sclerosis (MS)

Sponsor: NYU Langone Health

6 states386 participantsDetails ›

RecruitingPhase 2

A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients

Sponsor: Tiziana Life Sciences LTD

Foralumab · Placebo

5 states54 participantsDetails ›

RecruitingNA

Vascular Mechanisms, Functional Outcomes, & Exercise Among Persons With Multiple Sclerosis With Hypertension

Sponsor: University of Massachusetts, Boston

Home-based aerobic training

1 state80 participantsDetails ›

RecruitingPhase 2

Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis

Sponsor: Tiziana Life Sciences LTD

Foralumab TZLS-401 100 µg

1 state55 participantsDetails ›

Recruiting

Prevalence and Impact of Obstructive Sleep Apnea in Multiple Sclerosis

Sponsor: Beth Israel Deaconess Medical Center

1 state800 participantsDetails ›

Recruiting

Genes and Environment in Multiple Sclerosis

Sponsor: Columbia University

4 states5000 participantsDetails ›

RecruitingPhase 1

Investigating the Utility of Demyelination Tracer [18F]3F4AP in Controls and Multiple Sclerosis Subjects

Sponsor: Massachusetts General Hospital

F-18 3F4AP

1 state60 participantsDetails ›

Recruiting

IConquerMS™ - a Patient-Powered Research Network for Multiple Sclerosis

Sponsor: Accelerated Cure Project for Multiple Sclerosis

1 state20000 participantsDetails ›

Recruiting

A Single-Center Study to Characterize the Safety and Efficacy of Ublituximab in Older Adults With Relapsing Forms of Multiple Sclerosis (RMS)

Sponsor: Neurology Center of New England P.C.

Ublituximab

1 state20 participantsDetails ›

Recruiting

Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

Sponsor: Sanguine Biosciences

Specimen sample

1 state20000 participantsDetails ›

RecruitingPhase 1

A Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of IMS001 in Subjects With Multiple Sclerosis

Sponsor: ImStem Biotechnology

IMS001

3 states30 participantsDetails ›

By invitation only

CorEvitas Multiple Sclerosis (MS) Registry

Sponsor: CorEvitas

1 state1000 participantsDetails ›

By invitation onlyPhase 2

Effects of Antiviral Therapies on Epstein-Barr Virus Replication

Sponsor: Massachusetts General Hospital

Truvada (tenofovir/emtricitabine)

1 state50 participantsDetails ›

Closed to new patientsPhase 3

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)

Sponsor: Hoffmann-La Roche

Ocrelizumab · Ocrelizumab

16 states769 participantsDetails ›

Closed to new patientsPhase 3

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Sponsor: Novartis Pharmaceuticals

Remibrutinib · Teriflunomide

23 states1011 participantsDetails ›

Closed to new patientsPhase 4

A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation

Sponsor: Novartis Pharmaceuticals

Ofatumumab · Disease modifying treatment (DMT)

19 states136 participantsDetails ›

Closed to new patientsPhase 3

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis

Sponsor: Hoffmann-La Roche

Fenebrutinib · Ocrelizumab

24 states985 participantsDetails ›

Closed to new patientsPhase 4

Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis

Sponsor: Novartis Pharmaceuticals

Ofatunumab

4 states24 participantsDetails ›

Closed to new patients

A Novel Wearable Digital Biomarker for Detecting Changes in Multiple Sclerosis (MS) Condition

Sponsor: Celestra Health Systems

1 state90 participantsDetails ›

Closed to new patientsPhase 3

Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)

Sponsor: Hoffmann-La Roche

Fenebrutinib · Teriflunomide

13 states751 participantsDetails ›

Closed to new patientsPhase 3

Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

Sponsor: Novartis Pharmaceuticals

Ofatumumab · Tetanus toxoid (TT) containing vaccin…

32 states1882 participantsDetails ›

Closed to new patientsPhase 3

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Sponsor: Novartis Pharmaceuticals

Remibrutinib · Teriflunomide

27 states1001 participantsDetails ›

Closed to new patientsPhase 3

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)

Sponsor: Hoffmann-La Roche

Fenebrutinib · Teriflunomide

23 states746 participantsDetails ›

Closed to new patientsPhase 3

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)

Sponsor: Hoffmann-La Roche

Ocrelizumab · Ocrelizumab

20 states864 participantsDetails ›

Closed to new patientsPhase 3

A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.

Sponsor: Sanofi

Tolebrutinib · Placebo

27 states2500 participantsDetails ›

Closed to new patientsPhase 3

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis

Sponsor: Hoffmann-La Roche

Ocrelizumab

26 states1300 participantsDetails ›

Closed to new patientsPhase 3

A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis

Sponsor: Hoffmann-La Roche

Ocrelizumab

13 states927 participantsDetails ›

Closed to new patientsPhase 3

A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (RRMS)

Sponsor: Hoffmann-La Roche

Ocrelizumab · Ocrelizumab Placebo

11 states188 participantsDetails ›

Closed to new patientsPhase 2

A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis

Sponsor: Hoffmann-La Roche

Ocrelizumab

5 states23 participantsDetails ›

Closed to new patientsPhase 3

Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis

Sponsor: Novartis Pharmaceuticals

Interferon beta-1a · Fingolimod

8 states240 participantsDetails ›

Closed to new patientsPhase 2

A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)

Sponsor: Zenas BioPharma (USA), LLC

Obexelimab · Placebo

11 states93 participantsDetails ›

Closed to new patients

A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS)

Sponsor: Biogen

Diroximel Fumarate · Dimethyl Fumarate

1 state10500 participantsDetails ›

Closed to new patientsNA

Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial

Sponsor: Johns Hopkins University

Natalizumab/natalizumab-sztn, Alemtuz… · Glatiramer acetate, Interferons (intr…

28 states900 participantsDetails ›

Closed to new patients

Biobank For MS And Other Demyelinating Diseases

Sponsor: Accelerated Cure Project for Multiple Sclerosis

9 states3226 participantsDetails ›

Closed to new patients

A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)

Sponsor: Biogen

Natalizumab

1 state400 participantsDetails ›

The app

Check out the MS Buddy app

Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.

Active MS trials with sites in Massachusetts

MS trials in other states